Coya Therapeutics

Coya Therapeutics

Coya Therapeutics incorporated in 2020, founded by CEO Howard Berman and Dr. Stanley Appel, a leading neurologist and researcher at Houston Methodist Hospital. The company emerged from Dr. Appel's decades of work on the role of neuroinflammation in amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Coya is a publicly traded biotech (NASDAQ: COYA), not a family office or fund, focused wholly on developing its own therapeutic pipeline. The firm's strategy centers on autologous and allogeneic regulatory T cell (Treg) platforms aimed at suppressing the chronic inflammation that accelerates diseases like ALS, frontotemporal dementia, and Parkinson's disease. Its lead asset, COYA 301, is an autologous Treg cell therapy that entered a Phase 2 investigator-initiated trial for ALS at Houston Methodist. A second asset, COYA 302, combines two biologic agents — low-dose interleukin-2 and a CTLA-4 immunoglobulin — designed to boost endogenous Treg function. A Phase 2 proof-of-concept study for ALS, published in 2022, showed that COYA 302 slowed functional decline in a small patient cohort over 48 weeks (per Journal of Neurology, Neurosurgery & Psychiatry, 2022). Coya also evaluates its pipeline in Parkinson's disease and Alzheimer's disease, where neuroinflammation is a validated but underexploited target. Coya operates from a single headquarters in Houston, Texas, leveraging its roots at the Houston Methodist Neurological Institute. The scientific founders include Dr. Appel and Dr. Alireza Faridar, a neuroimmunology researcher. As a development-stage company, Coya reports no revenues and funds its operations through public-market raises and equity-linked financings. Its market capitalization provides a rough proxy for enterprise scale, though it deploys capital only into its own clinical programs. A February 2024 8-K filing disclosed the company had entered into an equity distribution agreement to raise up to $50 million from time to time, supporting continued development through Phase 2 data readouts expected in 2025. What structurally separates Coya from other neurodegenerative biotechs is its singular focus on regulatory T cells as the therapeutic mechanism. While most late-stage Alzheimer's and ALS programs target amyloid, tau, or genetic mutations, Coya argues that dampening chronic neuroinflammation is the prerequisite step that makes other interventions viable. This positions the company as a biology-first pure play with deep academic lineage — an architecture that, if clinically validated, offers both a first-mover advantage in a novel drug class and a tight feedback loop between Houston Methodist's trial infrastructure and Coya's preclinical programs.